Skip to search formSkip to main contentSkip to account menu

Vandetanib

An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Highly Cited
2012
Highly Cited
2012
PURPOSE There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral… 
Highly Cited
2011
Highly Cited
2011
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor… 
Highly Cited
2011
Highly Cited
2011
UNLABELLED The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the… 
Highly Cited
2010
Highly Cited
2010
PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating… 
Highly Cited
2010
Highly Cited
2010
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor… 
Review
2007
Review
2007
Multiple cellular pathways influence the growth and metastatic potential of tumors. This creates heterogeneity, redundancy, and… 
Review
2007
Review
2007
  • P. Wardman
  • Clinical oncology (Royal College of Radiologists…
  • 2007
  • Corpus ID: 34738474
Highly Cited
2007
Highly Cited
2007
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor…